The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. As the global voice of the sector, ARM represents the interests of 400+ members across 25 countries, including small and large companies, academic research institutions, major medical centers and patient groups. The Cell & Gene Meeting on the Mediterranean is the leading conference bringing together the ATMP community from Europe and beyond.
Register now for Meeting on the Med here: https://alliancerm.swoogo.com/meetingonthemed2022.
CELL & GENE MEETING ON THE MED 2022 NEWS
GVW and L7 discuss collaboration at Meeting on the MedApril 29, 2022 -- At the Cell & Gene Meeting on the Med in Barcelona, Spain, ScienceBoard.net spoke with Louis Hendriks, managing director at Global Value Web (GVW), and Vasu Rangadass, president and CEO at L7 Informatics, about the collaboration between the companies.
Forge Biologics shares plans for growth at Meeting on the MedApril 29, 2022 -- Chief commercial officer John Maslowski and senior vice president of business development Magdalena Tyrpien of Forge Biologics spoke with ScienceBoard.net at the Cell & Gene Meeting on the Med in Barcelona, Spain, to discuss the return to live events and in-person collaboration, Forge's expansion, and how Forge's corporate culture and vision works for their growth.
Mission Bio shares platform’s progress at Meeting on the MedApril 28, 2022 -- Mission Bio CEO Yan Zhang, PhD, and associate director of business development (cell and gene therapies) Nori Ueno spoke with ScienceBoard.net at the Cell & Gene Meeting on the Med in Barcelona, Spain, about the company's recent accomplishments with Tapestri, Mission Bio's single-cell platform for DNA analysis.
Market access and patient education take center stage at Meeting on the MedApril 26, 2022 -- Companies and patient groups tackled reimbursement hurdles and access challenges in a discussion at the Cell & Gene Meeting on the Med last week in Barcelona, Spain. Titans of the pharmaceutical industry took the stage to discuss important issues facing the growing segment, including patient education, reimbursement, and clinical trials.
Cevec Pharmaceuticals CEO stresses challenges in producing AAV vectorsApril 26, 2022 -- It will be a real challenge to produce sufficient quantities of gene therapy products, in particular when it comes to adeno-associated virus (AAV) vectors, according to Nicole Faust, CEO and chief science officer of Cevec Pharmaceuticals. Faust talked to ScienceBoard.net at the Cell & Gene Meeting on the Med last week in Barcelona, Spain.
Investment continues in cell and gene sector, despite disruptionsApril 25, 2022 -- Investment in the cell and gene therapy sector remains robust, despite the disruptions over the last several years due to the COVID-19 pandemic. That's one of the take-home messages from this week's Cell & Gene Meeting on the Mediterranean, according to ScienceBoard Vice President of Digital Media Sales Walt Schoenborn and reporter Melisande Rouger, who were on site in Barcelona, Spain.
Regional government steps in to boost gene therapy manufacturing in SpainApril 22, 2022 -- BARCELONA, SPAIN -- Early cooperation between the government of the Basque region in northern Spain and companies can help boost manufacturing of gene therapies, according to Gotzone Sagardui, health minister for the Basque Country. ScienceBoard.net spoke with Sagardui during the Cell & Gene Meeting on the Med earlier this week.
Meeting on the Med opens with new data and eyes on the moneyApril 21, 2022 -- BARCELONA, SPAIN -- The Cell & Gene Meeting on the Med conference kicked off on April 20 as speakers assessed the current state of the cell and gene therapy sector and explored payment strategies for advanced therapies across the European Union.